Table 1.
Patient characteristics of our study cohort, comprising men who developed radiographic metastases after undergoing prior radical prostatectomy between July 1981 and July 2010
| Variables | Total sample size (N = 140) |
|---|---|
| Age in years, mean (SD) | 60 (5.2) |
| Race, N (%) | |
| Caucasian | 132 (94.3%) |
| Non-Caucasian | 8 (5.7%) |
| Clinical stage, N (%) | |
| cT1 | 32 (22.9%) |
| cT2 | 97 (69.3%) |
| cT3 | 9 (6.4%) |
| Preoperative PSA in ng/ml, mean (SD) | 13.6 (14.3) |
| Gleason score, N (%) | |
| ≤6 | 5 (3.6%) |
| 7 | 69 (49.3%) |
| 8–10 | 66 (47.1%) |
| Organ-confined disease, N (%) | |
| Yes | 13 (9.3%) |
| No | 127 (90.7%) |
| Extracapsular penetration, N (%) | |
| Yes | 106 (75.7%) |
| No | 34 (24.3%) |
| Seminal vesicle invasion, N (%) | |
| Yes | 64 (45.7%) |
| No | 76 (54.3%) |
| Lymph node involvement, N (%) | |
| Yes | 52 (37.1%) |
| No | 88 (62.9%) |
| Surgical margins, N (%) | |
| Positive | 46 (32.9%) |
| Negative | 94 (67.1%) |
| Time from prostatectomy to PSA recurrence, N (%) | |
| ≤3 years | 101 (72.1%) |
| >3 years | 39 (27.9%) |
| PSA doubling time (PSADT), N (%) | |
| <3 months | 30 (21.4%) |
| 3–9 months | 60 (42.9%) |
| 9–15 months | 25 (17.9%) |
| ≥15 months | 25 (17.9%) |
| Time from PSA recurrence to metastasis, N (%) | |
| ≤3 years | 81 (57.9%) |
| >3 years | 59 (42.1%) |
| Receipt of hormonal therapy (after metastasis), N (%) | |
| Yes | 129 (92.1%) |
| No | 11 (7.9%) |
| Numbera of metastases at first presentation, N (%) | |
| ≤3 | 97 (72.9%) |
| ≥4 | 36 (27.1%) |
| Site of first metastasis, N (%) | |
| Bone | 124 (88.6%) |
| Liver/lung/node | 16 (11.4%) |
| Painb with first metastasis, N (%) | |
| Yes | 38 (29.2%) |
| No | 92 (70.8%) |
| Receipt of bisphosphonate (after metastasis), N (%) | |
| Yes | 62 (53.0%) |
| No | 55 (47.0%) |
| ECOG status at first metastasis, N (%) | |
| ≥1 | 27 (20.8%) |
| 0 | 103 (79.2%) |
aThe number of metastases was taken to be the combined number of soft tissue and osseous metastases as determined by CT and bone scan, respectively.
bThe presence of cancer-related pain was based on a pain score of ≥1/10 on a standard 0–10 pain scale.